<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953355</url>
  </required_header>
  <id_info>
    <org_study_id>07/009</org_study_id>
    <nct_id>NCT00953355</nct_id>
  </id_info>
  <brief_title>Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients</brief_title>
  <official_title>Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Context: Metformin administration in women with polycystic ovary syndrome (PCOS) improves
      hormonal and metabolic patterns with beneficial effects in terms of reproductive outcomes and
      intermediate cardiovascular disease risk factors. Furthermore, reduced folate and vitamin
      B12, and increased homocysteine (Hcy) levels have been found in type-2 diabetes mellitus
      patients treated with metformin.

      Objective: To evaluate if metformin administration exerts any effects on Hcy levels, and if
      folate supplementation may improve endothelial structure and function in PCOS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty patients affected by PCOS without additional metabolic or cardiovascular diseases
      grouped in two age- and body mass index-matched treatment arms.

      Interventions: A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram
      daily) (experimental group, n=25) or placebo (control group, n=25) supplementation.

      In each patient were evaluated: Complete hormonal and metabolic patterns, serum Hcy, folate,
      vitamin B12, and endothelin-1 (ET-1) concentrations, brachial artery diameter at baseline
      (BAD-B) and after reactive hyperemia (BAD-RH), flow-mediated dilation (FMD), and intima-media
      thickness (IMT) on both common carotid arteries.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial structure and function</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome Metabolic outcome Endocrine outcome</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Anovulation</condition>
  <arm_group>
    <arm_group_label>Folate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Folate plus metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folate plus metformin</intervention_name>
    <description>A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).</description>
    <arm_group_label>Folate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo plus metformin</intervention_name>
    <description>A six-month course of metformin (1700 mg daily) plus placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOS

        Exclusion Criteria:

          -  age &lt;18 or &gt;35 years

          -  BMI &gt;35 kg/m2

          -  neoplastic, metabolic, hepatic, renal, and cardiovascular disorders

          -  Current or previous use of oral contraceptives, glucocorticoids, antiandrogens,
             ovulation induction agents, antidiabetic and anti-obesity drugs or other hormonal
             drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>&quot;Pugliese&quot; Hospital</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Palomba S, Falbo A, Giallauria F, Russo T, Tolino A, Zullo F, Colao A, Orio F. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care. 2010 Feb;33(2):246-51. doi: 10.2337/dc09-1516. Epub 2009 Nov 23.</citation>
    <PMID>19933994</PMID>
  </results_reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>November 2, 2010</last_update_submitted>
  <last_update_submitted_qc>November 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Anovulation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

